GlassScriptPhysician profile
Taylor Furbay
NPI 1134718984
$5,034.55
in general payments reported to CMS, 2019-2025
30 companies · $814 in 2025
The $814 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $486 · 2023: $1,762 · 2024: $1,972 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,548.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,675.02 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $753.48 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $402.48 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $400.71 | 2022-2025 | |
| Novo Nordisk INC | $269.76 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $204.11 | 2023-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.42 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $193.39 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $146.65 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.08 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $71.44 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $67.88 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Shield Therapeutics INC | $61.09 | 2023-2025 | Accrufer |
| Axsome Therapeutics, INC. | $50.66 | 2024-2025 | Auvelity, Sunosi |
| Gilead Sciences, INC. | $45.71 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $44.21 | 2022 | |
| Dexcom, INC. | $42.60 | 2023-2024 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $42.10 | 2023 | Zio Xt Patch |
| Edwards Lifesciences Corporation | $34.09 | 2024 | Sapien 3 Ultra Resilia |
| Otsuka America Pharmaceutical, INC. | $33.16 | 2024-2025 | Rexulti |
| Pulmonx Corporation | $29.88 | 2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Lucid Diagnostics INC. | $22.88 | 2024 | |
| Corcept Therapeutics | $21.56 | 2025 | Korlym |
| Phathom Pharmaceuticals, INC. | $20.39 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $18.59 | 2024 | Trelegy Ellipta |
| Esperion Therapeutics, INC. | $17.30 | 2024 | Nexletol |
| Xeris Pharmaceuticals, INC. | $17.08 | 2024 | Gvoke Hypopen |
| Eisai INC. | $15.64 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Furbay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.